김종승 (고려대학교)

한빛사논문

조회111

고려대학교

Biomaterials, Jul 02 2024, 311 S0142-9612(24)00230-8 | https://doi.org/10.1016/j.biomaterials.2024.122696 Bifunctional black phosphorus quantum dots platform: Delivery and remarkable immunotherapy enhancement of STING agonist

Yujun Zhang^a,b,c,1, Shijing Wang ^d,1, Hyeonji Rha ^e,1, Chang Xu ^a, Yue Pei ^a, Xiaoyuan Ji ^b, Junmin Zhang ^c, Ruitao Lu ^f, Shaochong Zhang ^d, Zhongjian Xie ^a, Jong Seung Kim ^e

^aShenzhen Children's Hospital, Clinical Medical College of Shenzhen University, Shenzhen University, Shenzhen, 518060, PR China

^bAcademy of Medical Engineering and Translational Medicine, Medical College, Tianjin University, Tianjin 300072, PR China

^cInternational Joint Research Center for Molecular Science, College of Chemistry and Environmental Engineering, Shenzhen University, Shenzhen, 518060, PR China

^dShenzhen Eye Hospital, Jinan University, Shenzhen Eye Institute, Shenzhen, 518040, PR China

^eDepartment of Chemistry, Korea University, Seoul, 02841, South Korea

^fShenzhen International Institute for Biomedical Research, Shenzhen, 518109, PR China

¹These authors have contributed equally.

Corresponding authors: Shaochong Zhang, Zhongjian Xie, Jong Seung Kim

Abstract

Cancer immunotherapy has been developed to improve therapeutic effects for patients by activating the innate immune stimulator of interferon gene (STING) pathway. However, most patients cannot benefit from this therapy, mainly due to the problems of excessively low immune responses and lack of tumor specificity. Herein, we report a solution to these two problems by developing a bifunctional platform of black phosphorus quantum dots (BPQDs) for STING agonists. Specifically, BPQDs could connect targeted functional groups and regulate surface zeta potential by coordinating metal ions to increase loading (over 5 times) while maintaining high universality (7 STING agonists). The controlled release of STING agonists enabled specific interactions with their proteins, activating the STING pathway and stimulating the secretion release of immunosuppressive factors by phosphorylating TBK1 and IFN-IRF3 and secreting high levels of immunostimulatory cytokines, including IL-6, IFN-α, and IFN-β. Moreover, the immunotherapy was enhanced was enhanced mild photothermal therapy (PTT) of BPQDs platform, producing enough T cells to eliminate tumors and prevent tumor recurrence. This work facilitates further research on targeted delivery of small-molecule immune drugs to enhance the development of clinical immunotherapy.

논문정보

형식Research article
게재일2024년 07월 (BRIC 등록일 2024-07-08)
연구진국내(교신)+국외 연구진
분야

댓글 작성 로그인

CV 열람하기

연락처 보기